Lumosa announced today (2024/7/24) that its LT3001, a novel treatment for acute ischemic stroke, has received approval from UK health authorities for Phase 2 clinical trials. This marks the completion of regulatory reviews in the US, Taiwan, and eight European countries (Germany, Spain, Italy, the Czech Republic, Greece, Portugal, and the United Kingdom), demonstrating Lumosa's international clinical development strategy.
LT3001 is a world-first innovative therapy combining thrombolysis and neuroprotection. Compared to existing rt-PA therapy, which only 3~5% of AIS patients can receive treatment and carries a risk of hemorrhage, LT3001 can be administered within a 24-hour therapeutic window, significantly improving treatment accessibility.
Approximately 15 million people suffer ischemic stroke annually worldwide, creating a significant medical need that demands innovative solutions. If successfully commercialized, LT3001 will capture a potential market of up to US$10.6 billion, creating significant commercial value for Lumosa.